Risk factors
Lexicon Pharmaceuticals (LXRX) risk factors
Item 1A of every Lexicon Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors36 risks2 new3 dropped6 reworded
Clinical and regulatory execution remains central: sotagliflozin HCM Phase 3, pilavapadin, and possible type 1 diabetes NDA resubmission.
Filed Mar 05, 2026 - FY2024 10-K risk factors37 risks
Heavy reliance on clinical success and FDA approval for drug candidates like pilavapadin, LX9851, and sotagliflozin.
Filed Mar 07, 2025